[Hyper-thermo chemotherapy of esophageal cancer with thermosensitive liposome, TAC-1043].
Antitumor activity of the thermosensitive liposome, TAC-1043, was examined. The TAC-1043, produced by Takeda Chemical Industries, Ltd., contained entrapped cisplatin in a large unilamellar vesicle (LUV). LUV is composed of dipalmitoylphosphatidyl choline (DPPC) and distearoylphosphatidyl choline (DSPC) in the ratio of 9:1. The in vitro sensitivity of TAC-1043 was examined by SDI assay with MTT, using human esophageal cancer cell lines (TE-2, KY). TAC-1043 was effective at the concentration of 10 micrograms/ml, 41 degrees C and 43 degrees C. The in vivo effect of TAC-1043 together with hyperthermia was examined using mouse tumor MM 48. TAC-1043 combined with hyperthermia significantly suppressed the tumor proliferation.
Dohmitsu
K
K
Dept. of Surgery II, Nagoya University School of Medicine.
Akiyama
S
S
Kawasaki
S
S
Kataoka
M
M
Kondoh
K
K
Yamauchi
M
M
Itoh
K
K
Watanabe
T
T
Takagi
H
H
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000008:administration & dosage; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004337:Drug Carriers; D004354:Drug Screening Assays, Antitumor; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D006358:Hot Temperature / Q000627:therapeutic use*; D006801:Humans; D008081:Liposomes; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000628:therapy; D051379:Mice; D010713:Phosphatidylcholines / Q000008:administration & dosage; D014407:Tumor Cells, Cultured
D004337:Drug Carriers; D008081:Liposomes; D010713:Phosphatidylcholines; D015060:1,2-Dipalmitoylphosphatidylcholine; C010942:1,2-distearoyllecithin; D002945:Cisplatin